Evidence map›Paper›PMID 41738163›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Assessing Aβ-independent effects of Module 42 on immune function in vitro.

Ishita Ajith, Souvika Bakshi, Emma Mead, Opher Gileadi, Vittorio L Katis, Paul E Brennan, Emory‐Sage‐SGC‐Jax TREAT‐AD Center, Katerina O Gospodinova

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ishita AjithCentre for Medicines Discovery, Oxford, UK.
Souvika BakshiCentre for Medicines Discovery, Oxford, UK.
Emma MeadCentre for Medicines Discovery, Oxford, UK.
Opher GileadiCentre for Medicines Discovery, Oxford, UK.
Vittorio L KatisCentre for Medicines Discovery, Oxford, UK.
Paul E BrennanCentre for Medicines Discovery, Oxford, UK.
Emory‐Sage‐SGC‐Jax TREAT‐AD Centeradknowledgeportal.org/TREATAD-ESS-Center.
Katerina O GospodinovaCentre for Medicines Discovery, Oxford, UK.ORCID https://orcid.org/0000-0003-4525-0460

Funding

TREAT AD Structural Biology CoreU54AG065187 · NIA · EMORY UNIVERSITY · PI Gregory W Carter, ALLAN I LEVEY · 2019 to 2026
$69.7M
NIA NIH HHS U54 AG065187the National Institute on Aging U54AG065187
6 · The paper itself

Abstract

introductionA deep multi-omic analysis of post mortem human brains has identified a new co-expression protein network - Module 42 (M42), strongly corelated with Alzheimer's disease (AD) pathology. M42 comprises 32 transmembrane and extracellular matrix (ECM)-associated proteins, including the amyloid precursor protein (APP) and apolipoprotein E (apoE), and its members have been implicated in amyloid beta (Aβ) pathology. We systematically evaluated the Aβ-independent effects of M42 on immune function in vitro.

methodsRecombinant M42 proteins were expressed and purified. Their effects on phagocytosis, intracellular signaling, and cell viability were assessed in human induced pluripotent stem cell-derived macrophages.

resultsTreatment with Midkine (MDK) reduced phagocytosis, while treatment with the ectodomain of Transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFF2) had the opposite effect. Both proteins promoted intracellular Ca DISCUSSION: Our results suggest an additional role for M42 in AD via regulating immune functions. HIGHLIGHTS: We tested M42 proteins for their effects on immune functions in vitro. Five proteins altered phagocytosis, and seven altered Ca

Indexed as

Amyloid beta-PeptidesMacrophagesMembrane ProteinsPhagocytosisAlzheimer DiseaseCell SurvivalHumansInduced Pluripotent Stem CellsSignal TransductionAmyloid beta-PeptidesMembrane ProteinsAlzheimer's diseaseimmune functionM42 proteinsmatrisome

Identifiers

PMID41738163
PMCPMC12933249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.